Treatment of Pancreatic Ascites with Somatostatin

Pezzilli, Raffaele; Gullo, Lucio; Stefano, Mirella Di; Ventrucci, Maurizio; Ancona, D.

doi:10.1097/00006676-199301000-00021

Cited by 7 publications

(6 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 3 summarizes the results achieved with octreotide, which seem comparable to those obtained by Gilason et al [13] and Pezzilli et al [15] using the naturally occur ring hormone.…”

Section: Pancreatic Ascitessupporting

confidence: 80%

Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts

et al. 1994

View full text Add to dashboard Cite

Naturally occurring somatostatin and, even more so, its analogue, octreotide, by virtue of its greater manageability, are used extensively today in various pancreatic and gastrointestinal disorders, where their potent secretion-inhibiting capacity is exploited. In a number of conditions such as pancreatic fistulas the beneficial efficacy of the hormone is now definitely established both for therapeutic and for prophylactic purposes, whereas, in the other disease areas analyzed here, its use appears to be as an adjuvant to more specific and more radical procedures. Future clarification as to indications, dosage regimens and treatment times may reveal more strictly curative uses of octreotide in its own right, though, even as things stand at present, its efficacy as a complementary measure is so self-evident as to prompt its inclusion in treatment schedules both for enterocutaneous fistulas and for ascites and pancreatic pseudocysts.

show abstract

“…Table 3 summarizes the results achieved with octreotide, which seem comparable to those obtained by Gilason et al [13] and Pezzilli et al [15] using the naturally occur ring hormone.…”

Section: Pancreatic Ascitessupporting

confidence: 80%

Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts

et al. 1994

View full text Add to dashboard Cite

show abstract

“…Experimental data show that a dose of 0.15 μg/kg/h is enough for reducing protein concentration and total pancreatic juice output, with a maximal effect rendered (reduction of 73.9 ± 5.4%) at a dose of 1.35 μg/kg/h (10,11). In the case of pancreatic ascites, a dose of 1.5 μg/kg/h was used (13). In other cases a bolus is given, followed by a maintenance dose of 50, 100, and 250 μg/h (10,11).…”

Section: Discussionmentioning

confidence: 99%

“…Somatostatin is known to have an inhibitory gastrointestinal and endocrine action. Among its effects are inhibition of secretin secretion (7,8), duodenal cholecystokinin (CCK) release (7‐9), and pancreatic exocrine secretion (1,7‐13). It also retards gastric emptying rate (7,8,12,14).…”

mentioning

confidence: 99%

“…Most studies indicate a beneficial effect of the use of somatostatin in the management of acute pancreatitis (1,9,10), fistula closure (7,12,15), and even in the treatment of the rare complication of pancreatic ascites (7,13). Although reports on octreotide treatment in children exist, there are no data on the use of somatostatin for the treatment of acute pancreatitis or pancreatic pseudocysts in children.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin in the Treatment of a Pancreatic Pseudocyst in a Child

Bosman‐Vermeeren,

Veereman‐Wauters,

Broos

et al. 1996

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

SummaryPancreatic pseudocyst is a know complication of acute pancreatitis and pancreatic trauma. The treatment of pancreatitis remains a challenge and the pancreatic pseudocyst is often approached surgically. Lately, the use of somatostatin and its long‐acting analogue octreotide have proved useful in the treatment of pancreatitis and its complications in adults. This is the first report on the use of somatostatin in the treatment of a pancreatic pseudocyst in a child. We present the case of a posttraumatic pancreatic pseudocyst in a 10‐year‐old boy, regressing rapidly under somatostatin treatment, by which means surgical re‐intervention could be avoided.

show abstract

“…In 3 patients in whom conventional medical treatment failed, the addition of SMS 201-995 to the medical therapy led to the resolution of ascites after 10 days [43]. Pezzilli et al [44] and Rushlorth et al [45] achieved similar results in a 7-month old infant.…”

Section: Ascitesmentioning

confidence: 99%

Role of Somatostatin and Octreotide in the Treatment of Pancreatic Pseudocyst, Fistula and Ascites

Grauer

Barkin

1994

Digestion

View full text Add to dashboard Cite

Somatostatin and its analogue (SMS 201-995, octreotide) have proven to effectively inhibit various gastrointestinal functions including exocrine and neuroendocrine secretion, motility and splanchnic blood flow. The long half-life and the ability to administer the analogue subcutaneously has liberalized its use in different intestinal and extraintestinal disorders. In particular, the profound inhibitory effects on exocrine pancreatic function have prompted the use of SMS in several pancreatic disorders. Despite the lack of controlled studies, somatostatin has been used in different pancreatic disorders, fistulas, pseudocysts and ascites. The preliminary evidence supports a definite role of this analogue as adjunctive and primary therapeutic agents.

show abstract

Treatment of Pancreatic Ascites with Somatostatin

Cited by 7 publications

References 2 publications

Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts

Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts

Somatostatin in the Treatment of a Pancreatic Pseudocyst in a Child

Role of Somatostatin and Octreotide in the Treatment of Pancreatic Pseudocyst, Fistula and Ascites

Contact Info

Product

Resources

About